Table 5.
Clinical characteristics and prognosis of patients with m.3243 A>G by pathologic diagnosis
| Characteristics of cases with mtDNA point mutation (N = 44) | Pathologic diagnosis |
||
|---|---|---|---|
| FSGS (n = 21) | Nephrosclerosis (n = 5) | Diabetic nephropathy (n = 7) | |
| Data at kidney biopsy, median (IQR) | |||
| Age (yr) | 25.0 (18.0–30.0) | 30.0 (25.0–31.0) | 43.0 (33.0–61.0) |
| eGFR (ml/min per 1.73 m2) | 82.3 (56.8–108.9) | 44.6 (31.6–47.5) | 43.9 (33.7–85.8) |
| Proteinuria (g/g Cre) | 1.99 (1.330–4.41) | 0.24 (0.04–0.97) | 1.28 (0.60–2.35) |
| Observation time for initiation of RRT, median (IQR) (yr)a | 14.0 (8.0–16.0) | 6.0 (5.0–8.0) | 13.0 (5.0–18.0) |
| Initiation RRT, n (%) | 15 (71.4) | 1 (20.0) | 2 (42.9) |
| Observation time for all-cause mortality, median (IQR) (yr)a | 16.0 (9.0–24.0) | 8.0 (6.0–12.0) | 13.0 (6.0–23.0) |
| All-cause mortality, n (%) | 4 (19.1) | 1 (20.0) | 6 (85.7) |
| eGFR declining slope (ml/min per 1.73 m2/yr), median (IQR) | 8.3 (4.7–13.6) | 2.9 (1.7–4.5) | 3.3 (0.02–16.4) |
Cre, creatinine; eGFR, estimated glomerular filtration rate; FSGS, focal segmental glomerular sclerosis; IQR, interquartile range; mtDNA, mitochondrial DNA; RRT, renal replacement therapy.
a
Time from onset of renal manifestations.